PDCD1 and neoplasm: Numerous preclinical solid tumor models have demonstrated that the immune checkpoint blockade of PD-1/PD-L1 interaction prevents T cell exhaustion, resulting in enhanced anti-tumor immune activity and improved MS (9, 319, 320).